Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia
The DOI matches its Crossref record; 33 of the 35 references it cites were found in a registry or an index.
Abstract
Background Exagamglogene autotemcel (exa-cel) is a nonviral cell therapy designed to reactivate fetal hemoglobin synthesis through ex vivo clustered regularly interspaced short palindromic repeats (CRISPR)–Cas9 gene editing of the erythroid-specific enhancer region of BCL11A in autologous CD34+ hematopoietic stem and progenitor cells (HSPCs). Methods We conducted an open-label, single-group, phase 3 study of exa-cel in patients 12 to 35 years of age with transfusion-dependent β-thalassemia and a β 0 /β 0 , β 0 /β 0 -like, or non–β 0 /β 0 -like genotype. CD34+ HSPCs were edited by means of CRISPR-Cas9 with a guide mRNA. Before the exa-cel infusion, patients underwent myeloablative conditioning with pharmacokinetically dose-adjusted busulfan. The primary end point was transfusion independence, defined as a weighted average hemoglobin level of 9 g per deciliter or higher without red-cell transfusion for at least 12 consecutive months. Total and fetal hemoglobin concentrations and safety were also assessed. Results A total of 52 patients with transfusion-dependent β-thalassemia received exa-cel and were included in this prespecified interim analysis; the median follow-up was 20.4 months (range, 2.1 to 48.1). Neutrophils and platelets engrafted in each patient. Among the 35 patients with sufficient follow-up data for evaluation, transfusion independence occurred in 32 (91%; 95% confidence interval, 77 to 98; P<0.001 against the null hypothesis of a 50% response). During transfusion independence, the mean total hemoglobin level was 13.1 g per deciliter and the mean fetal hemoglobin level was 11.9 g per deciliter, and fetal hemoglobin had a pancellular distribution (≥94% of red cells). The safety profile of exa-cel was generally consistent with that of myeloablative busulfan conditioning and autologous HSPC transplantation. No deaths or cancers occurred. Conclusions Treatment with exa-cel, preceded by myeloablation, resulted in transfusion independence in 91% of patients with transfusion-dependent β-thalassemia. (Supported by Vertex Pharmaceuticals and CRISPR Therapeutics; CLIMB THAL-111 ClinicalTrials.gov number, NCT03655678 .)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia
Frangoul, H., Altshuler, D., Cappellini, M. D., Chen, Y.-S., Domm, J., Eustace, B. K., Foell, J., de la Fuente, J., Grupp, S., Handgretinger, R., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2031054 · Cited by 1,962
Self-citationBCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis
Canver, M. C., Smith, E. C., Sher, F., Pinello, L., Sanjana, N. E., Shalem, O., Chen, D. D., Schupp, P. G., Vinjamur, D. S., Garcia, S. P., et al. (2015) · Nature · doi:10.1038/nature15521 · Cited by 886
Cao, A., & Galanello, R. (2010) · Genetics in Medicine · doi:10.1097/gim.0b013e3181cd68ed · Cited by 722
An Erythroid Enhancer of BCL11A Subject to Genetic Variation Determines Fetal Hemoglobin Level
Bauer, D. E., Kamran, S. C., Lessard, S., Xu, J., Fujiwara, Y., Lin, C., Shao, Z., Canver, M. C., Smith, E. C., Pinello, L., et al. (2013) · Science · doi:10.1126/science.1242088 · Cited by 653
Origa, R. (2017) · Genetics in Medicine · doi:10.1038/gim.2016.173 · Cited by 509
Exagamglogene Autotemcel for Severe Sickle Cell Disease
Frangoul, H., Locatelli, F., Sharma, A., Bhatia, M., Mapara, M., Molinari, L., Wall, D., Liem, R. I., Telfer, P., Shah, A. J., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2309676 · Cited by 493
Self-citationTaher, A. T., Musallam, K. M., & Cappellini, M. D. (2021) · New England Journal of Medicine · doi:10.1056/nejmra2021838 · Cited by 477
Self-citationResults of Long-Term Iron-Chelating Therapy
Gabutti, V., & Piga, A. (2009) · Acta Haematologica · doi:10.1159/000203853 · Cited by 378
Corbacioglu, S., Carreras, E., Ansari, M., Balduzzi, A., Cesaro, S., Dalle, J.-H., Dignan, F., Gibson, B., Guengoer, T., Gruhn, B., et al. (2018) · Bone Marrow Transplantation · doi:10.1038/bmt.2017.161 · Cited by 363
Self-citationThe switch from fetal to adult hemoglobin.
Sankaran, V. G., & Orkin, S. H. (2013) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a011643 · Cited by 333
Research works printed but not linked: 1
- Origa R. Beta-thalassemia. In: Adam MP, Mirzaa GM, Pagon RA, et al., eds. GeneReviews. Seattle: University of Washington, 1993.
Cited by
Items 201–245 of 245
Genetically enhanced mesenchymal stem cells for aging intervention
Jing-Hui, L. E. I., Guang-Hui, L. I. U., & Wang, S. (2026) · Shengming kexue · doi:10.3724/cbls.2026094
Joshi, G., Natarajan, N., Dickerson, K. E., & Voit, R. A. (2026) · British Journal of Haematology · doi:10.1111/bjh.70675
Badru, M. D., Ghansah, V., Adesanya, I. O., et al. (2026) · Australian Journal of Biomedical Research · doi:10.63946/aubiomed/18967
Franceschi, L. D., Aljurf, M. D., BARONCIANI, D., Bento, C., Chabannon, C., Corbacioglu, S., de la Fuente, J., Forni, G. L., Kattamis, A., Locatelli, F., et al. (2026) · Bone Marrow Transplantation · doi:10.1038/s41409-026-02947-5
Self-citationYu, M., Das, P., Zhang, X., & Cheng, X. (2026) · Molecular Oncology · doi:10.1002/1878-0261.70304 · Cited by 1
“Clinical studies have demonstrated that this approach results in transfusion independence in b -thalassemia and elimination of vaso-occlusive crises in SCD [3,70].”
Gene editing of hematopoietic stem cells: applications and advances
Li, Q., Wang, H., He, Y., Hong, G., & Bao, G. (2026) · International Journal of Hematology · doi:10.1007/s12185-026-04251-w
Essa, M., Algeri, M., Alzahrani, M., Bernaudin, F., Bordon, V., Choudhury, S., de la Fuente, J., Giglio, F., Nur, E., Pinto, V. M., et al. (2026) · Bone Marrow Transplantation · doi:10.1038/s41409-026-02977-z · Cited by 1
Self-citationRecent advances of CRISPR-based gene editing technologies and delivery strategies
Xue, F., Xin, Z., Wang, G., Xing, J., Han, H., Zhao, X., & Song, N. H. (2026) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2026.2702869 · Cited by 1
Papingiotis, G., Mantzourani, M., Gogas, H., Filippatos, G. S., & Farmakis, D. T. (2026) · Heart Failure Reviews · doi:10.1007/s10741-026-10663-x
Zhang, Y., Yang, Y., Liu, Z., Li, Y., Xue, Y., Zhang, Z., Chen, G., Liu, J., He, M., Lu, T., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.08.006 · Cited by 2
Mazek, M., Ciebiera, M., & Massalska, D. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15166274
“Noninvasive prenatal testing (NIPT) was also developed for alpha-thalassemia screening [52].”
Unlocking the curative potential of gene transfer and editing for hematopoietic disorders
Shiroshita, K., Stolz, A., Malouf, C., Tran, V. L., Li, J., Weiss, M. J., & Naldini, L. (2026) · Experimental Hematology · doi:10.1016/j.exphem.2026.105493 · Cited by 1
On-target and off-target activities of CRISPR therapeutics across scales
Magdy, M., Gibson, J. R., Dhungana, A., Herring‐Nicholas, A., Cottle, R. N., & Josephs, E. A. (2026) · Trends in biotechnology · doi:10.1016/j.tibtech.2026.07.015 · Cited by 1
Hammoud, M. S., & Hanna, R. (2026) · JCO Oncology Practice · doi:10.1200/op-26-00479
Duminuco, A., Palumbo, G. A., Avella, E., Cupri, A., Garibaldi, B., Limoli, M. C., Mauro, E., Patti, S., Risata, N., Romano, S., et al. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15176520 · Cited by 1
“CRISPR-Cas9-edited autologous CD34+ cells (exagamglogene autotemcel) are approved for both transfusion-dependent β -thalassemia and severe sickle cell disease, alongside lentiviral β - globin gene-addition products [237,238].”
Gene therapy for hereditary hematological disorders: From clinical breakthroughs to future horizons
Chen, Z., Wang, W., Wu, Y., Qiang, Y., Cheng, W., & Liu, F. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.103075
Clinical Implementation of AI-Driven Gene and Cell Therapies
Manjunatha, I., Allen, T., & Sreeja, P. A. (2026) · Advances in computational intelligence and robotics book series · doi:10.4018/979-8-2600-0161-5.ch012
Hu, B., Gutty, V. S. R., Herzog, R. W., & Duan, D. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1930231
“It entails electroporation of an RNP complex composed of Cas9 and a sgRNA targeting a GATA-1 binding motif within the erythroid-specific enhancer region of the BCL11A gene in autologous CD34+ hematopoietic stem and progenitor cells (HSPCs) (10, 11).”
InfluentialTransfusionsmedizinische Versorgung bei Hämoglobinopathien
Cario, H. (2026) · Springer eBooks · doi:10.1007/978-3-662-71825-4_22
Lai, X., Liu, R., Xiao, H., Liu, L., Wei, Z., Shi, L., Wu, M., Zhang, Z., & Yongrong, L. (2026) · British Journal of Haematology · doi:10.1111/bjh.70819
An Integrated Gene Therapy Strategy for γ-Globin Addition and HbF Reactivation in β-Thalassemia
Paschoudi, K., Vasiloudis, N.-I., Papadopoulos, F., Nikolaou, X., Παπαδοπούλου, Α., Sova, P., Yannaki, E., & Psatha, N. (2026) · Thalassemia Reports · doi:10.3390/thalassrep16030019
Akhtar, M. S., & Amin, A. (2026) · Functional & Integrative Genomics · doi:10.1007/s10142-026-02026-4
“Phase 3 studies demonstrated elimination of severe vaso-occlusive crises for at least 12 months in 97% of evaluable patients with sickle cell disease and transfusion independence in 91% of patients with transfusion-dependent β-thalassemia (Frangoul et al. 2024a, b; Locatelli et al. 2024a, b ).”
Bartram, M. P., Cukoski, S., Scherrer, P., & Müller, R.-U. (2026) · Nephrologie aktuell · doi:10.1055/a-2835-9943
Makis, A. C., Saougou, I., & Vlahos, A. P. (2026) · Thalassemia Reports · doi:10.3390/thalassrep16030022
“Gene-addition therapy with betibeglogene autotemcel has achieved transfusion independence in most patients with non-β 0/ β 0 TDT, while CRISPR-Cas9 gene editing with exagamglogene autotemcel has produced similarly high rates of transfusion independence in phase 3 studies [86,87].”
Advancing Gene Editing for Children with Hemoglobinopathies
Thompson, A. A. (2026) · New England Journal of Medicine · doi:10.1056/nejme2607923
Making space for cures: Conditioning for autologous hematopoietic stem cell gene therapies
Crees, Z. D., DiPersio, J. F., & Persaud, S. P. (2026) · Seminars in Hematology · doi:10.1053/j.seminhematol.2026.09.001
Mitapivat for transfusion-dependent α-thalassaemia and β-thalassaemia
Frangoul, H., & Hussein, A. A. (2026) · The Lancet · doi:10.1016/s0140-6736(26)01609-0
Self-citationClinical translation of CRISPR-Cas9 therapeutics in cancer and inherited genetic disorders
Bashir, K., Vasudev, P., Chhetri, V., Dubhashi, D. P., Teli, Y. G., Biswas, R., Ramaiah, S., & Anbarasu, A. (2026) · Frontiers in Genome Editing · doi:10.3389/fgeed.2026.1868779
Gene therapy for rare diseases: technological innovation and clinical translation
ZHANG, Y.-J., & Yuan, H. (2026) · Shengming kexue · doi:10.3724/cbls.2026132
2026 Update on Clinical Trials in β‐Thalassemia
Musallam, K. M., Locatelli, F., Algeri, M., Cappellini, M. D., & Taher, A. T. (2026) · American Journal of Hematology · doi:10.1002/ajh.70472 · Cited by 1
Self-citationTargeted genomic integration and rearrangement using prime assembly
Levesque, S., Kawashima, N., Hwang, G., Zeng, J., Toskov, V., Barry, T., Mannherz, W. P., Homfeldt, L., Becerra, B., Schoonenberg, V. A. C., et al. (2026) · Nature · doi:10.1038/s41586-026-11024-2 · Cited by 7
Castro, D. A. W., Perugachi, A. C. M., & Fuel, M. (2026) · Hemoglobin · doi:10.1080/03630269.2026.2729189
The CRISPR/Cas technology landscape: From molecular mechanisms to multidisciplinary applications
Liu, Z., Yang, Y., Li, Z., Li, P., Jia, J., Qiao, X., Su, Y., Qin, Y., Wang, H., Dai, Y., et al. (2026) · Genes & Diseases · doi:10.1016/j.gendis.2026.102484
Kapoor, U., & Bhatia, M. (2026) · Seminars in Hematology · doi:10.1053/j.seminhematol.2026.09.004
Wen, Z., & Su, J. (2026) · Clinical and Translational Medicine · doi:10.1002/ctm2.70764 · Cited by 1
RNA therapeutics: current status and future directions
Yang, B., Sedano, M. J., Perez, K. L., Vijayaraghavan, M., Reid, V. A., Yallapu, M. M., Chauhan, S. C., Dhandayuthapani, S., Ramos, E., & Gadad, S. S. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-03032-5 · Cited by 1
“345,346 Fetal γ - globin (HbF) production decreases after birth through repression by the BCL11A transcription factor, 347 as part of normal gene regulation, while β -globin expression takes place.”
A review of genetic modification for ex vivo cellular therapies
Dinh, A., Zhang, N., & Stroncek, D. F. (2026) · Transfusion · doi:10.1111/trf.70163
Precision reactivation of fetal hemoglobin: expanding the gene-editing landscape for β-thalassemia
Xie, S., & Ye, Y. (2026) · Journal of Translational Genetics and Genomics · doi:10.20517/jtgg.2026.88
“The pharmacological potential of CRISPR-Cas9: Revolutionizing gene therapy and drug development”
Acharyya, S., Behera, B., Pradhan, R., Debata, J., Patra, P. K., Giri, S., & Kumar, H. K. S. (2026) · Nucleosides Nucleotides & Nucleic Acids · doi:10.1080/15257770.2026.2740083
Human genetics implicates a BACH2–NRF2 axis in fetal haemoglobin activation
Guo, C., Arora, U. P., Cheng, X., Xu, W., Cato, L. D., Li, R., Lu, H. Y., Lee, A., Yu, F., Agarwal, G., et al. (2026) · Nature · doi:10.1038/s41586-026-11113-2 · Cited by 11
Evolution of Gene Therapy in Hematology
Loves, R. H., & Kohn, D. B. (2026) · Seminars in Hematology · doi:10.1053/j.seminhematol.2026.09.005
Small populations, big impact: leveraging rare disease gene therapies to benefit millions
Cherqui, S. (2026) · Journal of Clinical Investigation · doi:10.1172/jci212036
Reactivation of the embryonic ζ-globin gene ameliorates severe forms of α-thalassemia
Liu, S., Ejaz, A., King, A. J., Olijnik, A.-A., Sloane-Stanley, J. A., Scott, C., Amid, A., Biggs, D., Davies, B., Eglinton, J., et al. (2026) · Nature Genetics · doi:10.1038/s41588-026-02770-0
Gene therapy for hemoglobinopathies
Gibson, N. M., Patel, J., & Kwiatkowski, J. L. (2026) · Seminars in Hematology · doi:10.1053/j.seminhematol.2026.09.014
Self-citationCurrent translational perspectives for diagnosis and individualized therapy in rare genetic diseases
Niazi, S. K. (2026) · Communications Medicine · doi:10.1038/s43856-026-01962-3
“The CLIMB SCD-121 trial demonstrated a sustained absence of severe vaso-occlusive crises for at least 12 months in 29 of 30 evaluable patients 50 , whereas CLIMB THAL-111 reported transfusion independence in 32 of 35 evaluable patients 51 .”
Metadata
- Authors
- Locatelli, F., Lang, P., Wall, D., Meisel, R., Corbacioglu, S., Li, A. M., de la Fuente, J., Shah, A. J., Carpenter, B., Kwiatkowski, J. L., Mapara, M., Liem, R. I., Cappellini, M. D., Algeri, M., Kattamis, A., Sheth, S., Grupp, S., Handgretinger, R., Kohli, P., Shi, D., Ross, L., Bobruff, Y., Simard, C., Zhang, L., Morrow, P. K., Hobbs, W. E., & Frangoul, H.
- Affiliations
- Università Cattolica del Sacro Cuore (IT)
- From IRCCS Ospedale Pediatrico Bambino Gesù (F.L., M.A.) and Catholic University of the Sacred Heart (F.L.), Rome, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan (M.D.C.), and the Department of Health Sciences, Magna Graecia University, Catanzaro (M.A.) — all in Italy; University Children’s Hospital Tübingen (R.H.), and the Cluster of Excellence iFIT (EXC 2180) “Image-guided and Functionally Instructed Tumor Therapies” and the German Cancer Consortium, Partner Site Tübingen, University of Tübingen (P.L.), Tübingen, the Division of Pediatric Stem Cell Therapy, Department of Pediatric Oncology, Hematology, and Clinical Immunology, Medical Faculty, Heinrich Heine University, Düsseldorf (R.M.), and the University of Regensburg, Regensburg (S.C.) — all in Germany; the Hospital for Sick Children and University of Toronto, Toronto (D.W.), and BC Children’s Hospital, University of British Columbia, Vancouver (A.M.L.) — all in Canada; Imperial College Healthcare NHS Trust, St. Mary’s Hospital (J.F...
- ORCID
- Locatelli, Franco
- Lang, Peter
- Wall, Donna
- Meisel, Roland
- Corbacioglu, Selim
- Li, Amanda M.
- Shah, Ami J.
- Carpenter, Ben
- Kwiatkowski, Janet L.
- Mapara, Markus
- Liem, Robert I.
- Cappellini, Maria Domenica
- Algeri, Mattia
- Kattamis, Antonis
- Sheth, Sujit
- Grupp, Stephan
- Handgretinger, Rupert
- Kohli, Puja
- Zhang, Lanju
- Morrow, Phuong Khanh
- Frangoul, Haydar
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-05-09
- Volume
- 390
- Issue
- 18
- Pages
- 1663-1676
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4395068362
- Cited by
- 253
- References
- 35
- Citations by year
- 2026: 128 · 2025: 89 · 2024: 35
- FWCI
- 70.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- CRISPR Therapeutics
- Vertex Pharmaceuticals
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Keywords
- exagamglogene autotemcel, beta-thalassemia, CRISPR/Cas9 genome editing, BCL11A, fetal hemoglobin, hematopoietic stem cell transplantation, myeloablative conditioning, busulfan, transfusion independence, non-viral gene therapy, autologous hematopoietic stem cells
- MeSH terms
- Gene Editing, Adolescent, Adult, Blood Transfusion, Busulfan, Child, Europe, Female, Fetal Hemoglobin, Hematopoietic Stem Cells, Humans, Male, North America, Repressor Proteins, Transplantation, Autologous, beta-Thalassemia, Hematopoietic Stem Cell Transplantation, Antigens, CD34, Transplantation Conditioning, Myeloablative Agonists, Young Adult, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.